Kinomica to Present Research Abstract on a Multi-drug Biomarker Signature to Predict Best First-line Treatments for Acute Myeloid Leukemia at the 2024 ASCO Annual Meeting

Kinomica Ltd.

Poster Title: Multi-drug algorithm to accurately predict best first-line treatments in newly-diagnosed acute myeloid leukemia (AML)

Presenter: Pedro Rodriguez Cutillas at Barts Cancer Institute

Authors: Pedro Rodriguez Cutillas[1], Weronika E. Borek[5], Josie A. Christopher[5], Luis Veiga Nobre[5], Amy Campbell[5], Janet Kelsall[5], Federico Pedicona[5], Nazrath Nawaz[5] , David N. Perkins[5] , Pedro Moreno Cardoso[5] , Andrea Arruda[2], Alexander Joseph Ambinder[3], Sayantanee Dutta[4], Paolo Gallipoli[1], Heinz Sill[4], Gabriel Ghiaur[3], Mark D. Minden[2], Andrew Williamson[5], John G. Gribben[1], Arran David Dokal[5]

Organizations: [1] Barts Cancer Institute, [2] Princess Margaret Cancer Centre, [3] Johns Hopkins University, [4] Medical University of Graz, [5] Kinomica Ltd

Poster Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Session Date and Time: Monday June 3, 2024, 9:00 AM - 12:00 PM CDT

Poster Board Number: 84

Abstract Presentation Number: 6525

The Abstract is available on the ASCO online itinerary planner here.

About Kinomica

Kinomica is a developer of precision oncology diagnostics. The company has developed KScan®, a phosphoproteomic diagnostic platform to help clinicians better realize the full potential of precision medicine by predicting which of the drugs currently approved to treat a disease a particular patient will respond best to, thereby aiding clinical decision making. Learn more at www.kinomica.com and follow us on LinkedIn.

Logo - https://mma.prnewswire.com/media/2422786/4729421/Kinomica_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/kinomica-to-present-research-abstract-on-a-multi-drug-biomarker-signature-to-predict-best-first-line-treatments-for-acute-myeloid-leukemia-aml-at-the-2024-asco-annual-meeting-302158004.html